Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q2 FY2025 Earnings Presentation
25 slides from Piramal Pharma's earnings presentation, October 2024
Slide 1: Q2 & H1 FY2025 Results
Q2 & H1 FY2025 Results October 2024
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 3: Key Performance Highlights of Q2FY25 / H1FY25
Key Performance Highlights of Q2FY25 / H1FY25 Healthy Revenue Growth… Historically, H2 has Outperformed H1 H1FY25 Revenue Break-up (In ₹ Crore) 17% 15% % of Full Year Revenue H1 H2 55 55 55 4,193 13% 3,660 1,911 2,242 45 45 45 30% 57% Q2FY24 Q2FY25 H1FY24 H1FY25 FY22 FY23 FY24 … Providing Impetus to
Slide 4: Key Performance Highlights of Q2FY25 / H1FY25: CDMO
Key Performance Highlights of Q2FY25 / H1FY25 Key Highlights Revenue (In ₹ Cr) and Growth 24% 21% • On-patent commercial orders continue to drive robust revenue growth 2,381 CDMO 1,967 • Improvement in EBITDA margin through operating leverage and cost optimization 1,324 1,068 • Customer led US$80Mn
Slide 5: Business Wise Performance
Business Wise Performance
Slide 6: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) ❖Improving Market Outlook: 24% 21% • Biotech funding improved over previous year, but remains uneven across months • Regulatory changes (e.g. Biosecure Act) and supply chain diversification driving increased customer enquires and visit
Slide 7: Heading in the Right Direction
Heading in the Right Direction Consistent Growth… …With Increasing Share of YoY CDMO Revenue Growth Innovation Related Work Differentiated Offerings % of CDMO Revenue % of CDMO Revenue 44% 29% 50% 27% 24% 35% 17% 18% 14% FY21 FY24 FY21 FY24 12% On-Patent Commercial Integrated Orders / Cross Selling
Slide 8: More than Doubling the Capacity at Lexington Facility
More than Doubling the Capacity at Lexington Facility This expansion to play a vital role in integrated antibody‐drug conjugate development and manufacturing US$80Mn Expansion to be completed by end of FY2027 • Over 2x capacity increase - From 104 annual batches to 240 annual batches • Additional 24
Slide 9: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) ❖Inhalation Anesthesia 9% 6% • Continue to witness good volume growth in Sevoflurane and Isoflurane 1,274 • Registering robust performance in emerging markets like Asia, Europe and RoW 1,206 • Capacity expansion at
Slide 10: Building a Portfolio of Differentiated and Specialty Products
Building a Portfolio of Differentiated and Specialty Products Addressable Market of Differentiated and Specialty Products Select Examples of Our Experience in Differentiated & Specialty Products United States Gablofen Mitigo • US$27 Bn* addressable injectable market (Intrathecal Therapy) (Intrathecal
Slide 11: India Consumer Healthcare Business
India Consumer Healthcare Business Performance Highlights Revenue Growth (In ₹ Crore) ❖New Product launches - 9 new products and 13 new SKUs launched in H1FY25. We have 8% 9% launched 150+ new products and SKUs in the last three years 541 495 ❖ Power Brands - Power Brands grew at 18% YoY during Q2 a
Slide 12: Media Spends and New Product Launches Driving Power Brands
Media Spends and New Product Launches Driving Power Brands Continuous Media and Trade Spends… …Fueling Growth of Power Brands… (In ₹ Crore) (In ₹ Crore) % of ICH 16% 15% 15% 13% 12% 448 sales 100% 45000% 90% 370 H1 200 40000% 80% 35000% H2 131 131 268 260 116 70% 150 30000% 60% 84 50% 194 25000% 100
Slide 13: Sustainability Initiatives
Sustainability Initiatives
Slide 14: Released our FY2024 Sustainability Report
Released our FY2024 Sustainability Report Key Highlights • The report follows GRI standards and is aligned with SASSB and UNGC frameworks, underscoring our commitment to sustainable growth, responsible capital allocation, and impactful stakeholder engagement • Third Party Assurance: The Report has b
Slide 15: Notable Highlights in our FY2024 Sustainability Report
Notable Highlights in our FY2024 Sustainability Report Business 30% Zero 37% 5% Of suppliers by value targeted Resilience Women representation in Board in FY2024 Cases of data breaches Of critical suppliers assessed on sustainability criteria for the supplier capacity- building programme by FY25 Res
Slide 16: SBTi Approved GHG Reduction Targets
SBTi Approved GHG Reduction Targets In Exclusive Club of Companies with SBTi1 Approved GHG2 Reduction Targets Only five3 Indian Pharmaceuticals, Biotechnology and Life Sciences companies with SBTi approved Near Term Targets Less than 253 Pharmaceuticals, Biotechnology and Life Sciences companies in
Slide 17: Financials
Financials
Slide 18: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q2FY25 Q2FY24 YoY Change Q1FY25 QoQ Change H1FY25 H1FY24 YoY Change Revenue from Operations* 2,242 1,911 17% 1,951 15% 4,193 3,660 15% CDMO 1,324 1,068 24% 1,057 25% 2,381 1,967 21% CHG 643 589 9% 631 2% 1,274 1,206 6% ICH 277 25
Slide 19: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Key Balance Sheet Items As on 30-Sep-24 As on 31-Mar-24 Total Equity 7,907 7,911 Net Debt 4,235 3,932 Total 12,143 11,843 Net Fixed Assets 9,096 9,106 Tangible Assets 4,298 4,250 Intangible Assets including goodwill 3,669 3,740 CWIP (includi
Slide 20: Strategic Goals
Strategic Goals
Slide 21: Financial Aspirations for FY2030
Financial Aspirations for FY2030 3x 2x 1x Over 3x Growth in More than Double the Reduce Leverage EBITDA Revenues on the Balance Sheet ~25% US$2+ Bn ~1x EBITDA Margins Revenue Net debt to EBITDA Exponential Growth Enhance ROCE in PAT Early Teens PAT Margins High Teens ROCE Note:- The aspirations ment
Slide 22: US$2+ Bn Company with 25% EBITDA Margin by FY2030
US$2+ Bn Company with 25% EDITDA Margin by FY2030 Strategic Goals for FY2030 US$1.2 Bn revenues with ~25% US$600 Mn revenues with 25%+ US$200 Mn revenues with double-digit EBITDA margin EBITDA margin EBITDA margin CDMO CHG ICH Emerge as a fast-growing, innovation- Become a leading critical care comp
Slide 23: Key Investment Highlights
Key Investment Highlights US$2+ Bn Global Pharma, Health & Wellness Company by FY2030 1 Strong promoter group with over 35 years of demonstrated ability to build scalable and differentiated businesses 2 Presence in large multi-billion dollar size attractive industry segments with promising tailwinds
Slide 24: Dial-in details for Q2 and H1 FY25 Earnings Conference Call
Dial-in details for Q2 and H1 FY25 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 05:00 PM IST 1 800 120 1221 (Toll free number) Conference USA – 07:30 AM Toll free number Call on 24th (Eastern Time – New York) 18667462133
Slide 25: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com